Thursday May 24, 9:02 am Eastern Time
Press Release
SOURCE: GenVec, Inc.
GenVec Demonstrates Tissue-Specific Gene Delivery
GAITHERSBURG, Md., May 24 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC - news), a leading gene therapy company, presented data today demonstrating tissue-specific gene delivery using its proprietary, targeted adenovector technology. These data were presented at the 101st Annual Meeting of The American Society for Microbiology, in Orlando, Florida.
In this most recent advance, a team of scientists, led by Dr. Thomas Wickham, GenVec's Director of Vector Targeting and Selectivity, showed that adenovectors could be molecularly modified to direct the delivery of genes to specific cells. The new vectors avoid binding to unwanted tissues, such as the liver, yet deliver genes to new targets with high efficiency. Selective gene delivery is a key element of GenVec's platform technologies, which are covered by over 350 issued, allowed or pending patents worldwide, including over 50 patents that have issued in the United States.
``This technology has the power to increase the specificity and safety of gene transfer for many important medical needs, including the treatment of cancer,'' said Dr. Rick King, GenVec's Vice President of Research. Dr. Imi Kovesdi, GenVec's Chief Scientific Officer added, ``These results further demonstrate GenVec's leadership position in gene delivery technology. We have the capacity to design new drugs, with built-in specificity, in a way never before possible.''
GenVec is a publicly held biotechnology company focused on the development and commercialization of novel gene-based therapies that produce medically beneficial proteins at the site of disease. The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as BIOBYPASS® angiogen and GENSTENT(TM) biologic, that address medical needs in the area of cardiovascular disease, TNFerade(TM) biologic for oncology and the PEDF program for ophthalmology. Additional information on GenVec is available at its web site located at genvec.com and in the company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements are typically identified by words or phrases such as ``believe,'' ``expect,'' ``anticipate,'' ``intend,'' ``estimate,'' ``assume,'' ``plan,'' ``outlook,'' ``prospect,'' and variations of such words and similar expressions, or future or conditional verbs such as ``will,'' ``would,'' ``should,'' ``could,'' ``may,'' or similar expressions. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. The following factors, among others, could cause actual results to differ materially from forward-looking statements or historical experience: risks relating to the early stage of product candidates under development, risks relating to GenVec's ability to identify and enter into agreements with potential collaborative partners, uncertainties relating to clinical trials, dependence on third parties, future capital needs, and risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks). GenVec's SEC reports identify additional factors that can affect forward-looking statements. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
SOURCE: GenVec, Inc. |
